Neuragen for Peripheral Diabetic Neuropathy

Overview

The purpose of this study is to determine if the use of Neuragen (a natural health product oil rubbed into the skin) is effective at reducing pain and improving the quality of life in people with diabetic peripheral neuropathy.

Full Title of Study: “The Safety and Efficacy of Neuragen in Diabetic Peripheral Neuropathy: A Double-blind Randomized Placebo Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)

Detailed Description

Incidence of diabetic neuropathy and development of diabetic ulcers varies based on the severity (lack of blood sugar control) and duration of diabetes. Estimates of rates of occurrence vary although one prospective study showed 7.2% of newly diagnosed ulcer-free diabetics developed ulcers within one year of being diagnosed. Current treatment initiatives aimed at educating diabetic patients on how to prevent diabetic ulcers and mange peripheral neuropathy have had varied success. Chronic pain is the number one reason that this population seeks help from medical professionals. Diabetics are particularly predisposed to a potentially disabling form of chronic pain known as peripheral neuropathy. In fact, over 50% of diabetics have painful neuropathy, or will develop this condition. Other than the primary goal of addressing blood sugar levels, conventional treatment of diabetic peripheral neuropathy involves prescription gabapentanoids or opiod analgesics, both of which have considerable cost and may be associated with side effects from long-term use and overall limited success rates. Neuragen is an over-the-counter natural health product that may be a safe and effective treatment option for this disease. Using a randomized double-blind placebo control clinical trial the effects of Neuragen on pain, function and quality of life will be assessed.

Interventions

  • Other: Neuragen
    • 2-3 drops applied topically 2-3 times per day as needed over a 3 month period
  • Other: Mineral oil
    • Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application

Arms, Groups and Cohorts

  • Experimental: Neuragen
    • Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
  • Sham Comparator: Mineral oil
    • Mineral oil, scent and color matched to intervention

Clinical Trial Outcome Measures

Primary Measures

  • Brief Pain Inventory for sustained relief
    • Time Frame: Baseline to month 3
  • Numeric pain scale (0-10) for immediate relief
    • Time Frame: Baseline compared to average daily measure over 3 months

Secondary Measures

  • NeuroQol-97 quality of life measurement questionnaire
    • Time Frame: Baseline to 3 months
  • Liver enzyme – AST
    • Time Frame: Baseline to 3 months
  • Liver enzyme – ALT
    • Time Frame: Baseline to 3 months
  • Liver enzyme – GGT
    • Time Frame: Baseline to 3 months
  • Neurologic impairment scale LL +7
    • Time Frame: Baseline to 3 months
  • Amount of medication used
    • Time Frame: Baseline to 3 months
  • Adverse event reports
    • Time Frame: Baseline to 3 months

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women of at least 18 years of age – Established diagnosis of neuropathic pain for at least the past 3 months duration, and type 1 or type 2 diabetes, confirmed by primary care physician and/or neurologist. By signing the informed consent, participants agree to have the study coordinator contact their physician for confirmation of diagnosis. – Pain of at least level 4 on a 0-10 scale, and not over 9, despite other treatments on intake. – Presence of dynamic tactile allodynia or pinprick hyperalgesia – Normal cognitive and communication skills (as judged by investigator) and ability to complete self-report questionnaires. Exclusion Criteria:

  • Pregnancy – Previous or continuing use of Neuragen® – Evidence of other types of pain as, or more severe, than the pain under study – Major psychological conditions requiring treatment – History of eczema/atopy/anaphylaxis or unusual skin reactions. This will be assessed using a subjective question (Have you ever suffered from eczema? Or experienced a skin reaction to a substance? Or experienced an anaphylactic reaction?) – Self reported sensitivity to perfumes, essential oils, odors. – Changes to current pain management regime within the previous month prior to start of study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The Canadian College of Naturopathic Medicine
  • Collaborator
    • Queen Elizabeth II Health Sciences Centre
  • Provider of Information About this Clinical Study
    • Principal Investigator: Kieran Cooley, Associate Director, Research – The Canadian College of Naturopathic Medicine
  • Overall Official(s)
    • Mary Lynch, MD, Study Chair, Dalhousie University
    • Kieran Cooley, ND, Principal Investigator, The Canadian College of Naturopathic Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.